Literature DB >> 12759253

Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.

Andrew D Rowan1, Wang Hui, Tim E Cawston, Carl D Richards.   

Abstract

Oncostatin M (OSM) is an interleukin (IL)-6 family cytokine that we have previously shown can synergize with a number of proinflammatory cytokines to promote the release of collagen from cartilage in explant culture. However, the effects of this potent cytokine combination in vivo are not known. Using adenoviral gene transfer, we have overexpressed murine IL-1 (AdmIL-1) and murine OSM (AdmOSM) intraarticularly in the knees of C57BL/6 mice. Histological analyses indicated marked synovial hyperplasia and inflammatory cell infiltration for both AdmIL-1 and AdmOSM but not in control joints. This inflammation was even more pronounced for the AdmIL-1+AdmOSM combination with evidence of cartilage and bone destruction. Significant loss of both proteoglycan and collagen was also seen for this combination, and immunohistochemistry revealed an increased expression of matrix metalloproteinases (MMPs) with decreased tissue inhibitor of metalloproteinases (TIMPs) in both articular cartilage and synovium. Similar expression profiles for MMPs/TIMPs were found in IL-1+OSM-stimulated human articular chondrocytes. Taken together, these data confirm that, in vivo, OSM can exacerbate the effects of IL-1 resulting in inflammation and tissue destruction characteristic of that seen in rheumatoid arthritis. We provide further evidence to implicate the up-regulation of MMPs as a key factor in joint pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759253      PMCID: PMC1868119          DOI: 10.1016/S0002-9440(10)64330-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

Review 1.  Targeting interleukin-1 in the treatment of rheumatoid arthritis.

Authors:  Jean-Michel Dayer; Barry Bresnihan
Journal:  Arthritis Rheum       Date:  2002-03

2.  A selective inhibitor of matrix metalloproteinases inhibits the migration of isolated osteoclasts by increasing the life span of podosomes.

Authors:  Tetsuya Goto; Hidefumi Maeda; Teruo Tanaka
Journal:  J Bone Miner Metab       Date:  2002       Impact factor: 2.626

3.  Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.

Authors:  G Cunnane; O Fitzgerald; C Beeton; T E Cawston; B Bresnihan
Journal:  Arthritis Rheum       Date:  2001-10

4.  Amelioration of arthritis in two murine models using antibodies to oncostatin M.

Authors:  C Plater-Zyberk; J Buckton; S Thompson; J Spaull; E Zanders; J Papworth; P F Life
Journal:  Arthritis Rheum       Date:  2001-11

Review 5.  Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators.

Authors:  Fons A J van de Loo; Wim B van den Berg
Journal:  Rheum Dis Clin North Am       Date:  2002-02       Impact factor: 2.670

6.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand.

Authors:  Alfons S K de Hooge; Fons A J van de Loo; Miranda B Bennink; Diana S de Jong; Onno J Arntz; Erik Lubberts; Carl D Richards; Wim B vandDen Berg
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

7.  Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways.

Authors:  J M Milner; S F Elliott; T E Cawston
Journal:  Arthritis Rheum       Date:  2001-09

8.  Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Authors:  A I Catrina; J Lampa; S Ernestam; E af Klint; J Bratt; L Klareskog; A-K Ulfgren
Journal:  Rheumatology (Oxford)       Date:  2002-05       Impact factor: 7.580

9.  Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice.

Authors:  G Schett; S Hayer; M Tohidast-Akrad; B J Schmid; S Lang; B Türk; F Kainberger; S Haralambous; G Kollias; A C Newby; Q Xu; G Steiner; J Smolen
Journal:  Arthritis Rheum       Date:  2001-12

10.  The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction.

Authors:  P J T Koshy; C J Lundy; A D Rowan; S Porter; D R Edwards; A Hogan; I M Clark; T E Cawston
Journal:  Arthritis Rheum       Date:  2002-04
View more
  24 in total

1.  Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection.

Authors:  Carey E Connelly; Yezhou Sun; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

2.  Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.

Authors:  W Hui; H E Barksby; D A Young; T E Cawston; N McKie; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

Review 3.  gp130 at the nexus of inflammation, autoimmunity, and cancer.

Authors:  J S Silver; C A Hunter
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

4.  Protein kinase C isoforms zeta and iota mediate collagenase expression and cartilage destruction via STAT3- and ERK-dependent c-fos induction.

Authors:  Gary J Litherland; Martina S Elias; Wang Hui; Christopher D Macdonald; Jonathon B Catterall; Matt J Barter; Matthew J Farren; Matthew Jefferson; Andrew D Rowan
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

5.  Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases.

Authors:  T G Morgan; A D Rowan; S C Dickinson; D Jones; A P Hollander; D Deehan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

6.  Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction.

Authors:  Siyoung Yang; Jonghwan Kim; Je-Hwang Ryu; Hwanhee Oh; Churl-Hong Chun; Byoung Ju Kim; Byoung Hyun Min; Jang-Soo Chun
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

7.  Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.

Authors:  Shahla Abdollahi-Roodsaz; Leo A B Joosten; Marije I Koenders; Ben T van den Brand; Fons A J van de Loo; Wim B van den Berg
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

8.  DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes.

Authors:  Ko Hashimoto; Richard O C Oreffo; Marc B Gibson; Mary B Goldring; Helmtrud I Roach
Journal:  Arthritis Rheum       Date:  2009-11

9.  Cytokine-induced MMP13 Expression in Human Chondrocytes Is Dependent on Activating Transcription Factor 3 (ATF3) Regulation.

Authors:  Chun Ming Chan; Christopher D Macdonald; Gary J Litherland; David J Wilkinson; Andrew Skelton; G Nicholas Europe-Finner; Andrew D Rowan
Journal:  J Biol Chem       Date:  2016-12-12       Impact factor: 5.157

10.  Dietary garlic and hip osteoarthritis: evidence of a protective effect and putative mechanism of action.

Authors:  Frances M K Williams; Jane Skinner; Tim D Spector; Aedin Cassidy; Ian M Clark; Rose M Davidson; Alex J MacGregor
Journal:  BMC Musculoskelet Disord       Date:  2010-12-08       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.